Gilead broke Intox's protein degradation technology in a $45 million deal

, Gilead Sciences, is using Nurix and its drug development technology to develop new cancer drugs that break down pathogenic proteins. If all follow-up payments and concessions are in place and realized, the big pharmaceutical companies will allocate $45 million in advance, worth up to $2.3 billion.Nurix's drug discovery platform focuses on manipulating ubibin systems that break down damaged or unwanted proteins. These proteins are labeled by ubibin (also proteins) and then transported to a protein complex called proteases, where they are degraded.The multi-year partnership will allow Nurix to use its technology to explore new drugs that use E3 connective enzymes - enzymes that control protein levels in human cells - leading to the degradation of specific protein targets, the two men said in a statement. Gilead has the option of developing up to five target licensing plans for the deal, and Nurix can choose to jointly develop up to two U.S. programs. In the 3d case, research and development costs, profits and losses will be split.
Related: Third Rock's Nurix has signed a $150 million immuno-oncology agreement with Celgenepartners target cancer and "other challenging diseases."“ There are a number of molecular targets that address disease pathways that have traditionally been difficult to operate using traditional methods," said John McHutchison, chief scientific officer of Gilead's research and development division, A.O. ,M.D。 "Nurix's innovative protein degradation discovery technology provides Gilead with a new strategy to ask about these drug targets as we continue to create a small molecular therapy channel for patients with cancer and other diseases," the statement said.Related: Cedilla Therapeutics invests $56 million in protein degradation in targeted cancerBased on our expertise in protein stabilization, this partnership expands our ability to build new channels of targeted protein degradation drugs while we continue to move our leadership program independently into clinical practice," Nurix CEO Arthur Sands said in a statement.The deal comes after Gilead attacked several others this year. Just last week, the company struck an infectious disease antibody agreement with Ab Cellera, and last month it teamed up with kidney specialist Goldfinch Bio for a total of $109 million.The partnerships could be worth more than $1 billion, with drug development specialist Insitro signing in May and Scholar Rock signing an agreement in December to address fibrosis, with Gilead paying more than $80 million in advance but worth up to $1.5 billion. (Compiled by this web)